ALKERMES | ALKS - Loan Capital


ALKERMES reported $285.82M in Loan Capital for its fiscal quarter ending in September of 2024.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Acadia Pharmaceuticals USD 0 0 Mar/2025
ALKERMES USD 285.82M 639K Sep/2024
Amgen USD 52.43B 1.33B Sep/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 596.66M 501K Sep/2025
Bristol-Myers Squibb USD 44.47B 1000K Sep/2025
Eli Lilly USD 40.87B 6.69B Sep/2025
Gilead Sciences USD 22.14B 5M Sep/2025
Ionis Pharmaceuticals USD 28.78M 596.71M Sep/2025
J&J USD 39.41B 173M Sep/2025
Malin Corporation EUR 0 0 Dec/2024
Merck USD 39.97B 6B Sep/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Otsuka Holdings JPY 160.57B 6.82B Sep/2025
Pfizer USD 57.41B 93M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025